Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 136, Issue , 2015, Pages 413-423

  Kesharwani, Prashant ^a   Xie, Lingxiao ^b   Mao, Guangzhao ^b   Padhye, Subhash ^c   Iyer, Arun K ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b Wayne State University   (United States)

^c UNIVERSITY OF PUNE   (India)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3, 4 Difluorobenzylidene curcumin; CD44 targeting; Drug delivery; Hyaluronic acid; PAMAM dendrimer; Pancreatic cancer

Indexed keywords

CELL CULTURE; CELLS; CYTOLOGY; DENDRIMERS; DISEASES; DRUG DELIVERY; FUNCTIONAL POLYMERS; ORGANIC ACIDS; PARTICLE SIZE;

CANCER CELL LINES; CD44 TARGETING; CURCUMIN; FLUORESCENCE STUDIES; PAMAM DENDRIMER; PANCREATIC CANCERS; POLYAMIDOAMINE DENDRIMERS; TARGETED DELIVERY;

HYALURONIC ACID;

3,4 DIFLUOROBENZYLIDENE CURCUMIN; CURCUMIN; DENDRIMER; HERMES ANTIGEN; HYALURONIC ACID; NANOCARRIER; POLYAMIDOAMINE; POLYAMIDOAMINE DENDRIMER; UNCLASSIFIED DRUG; 3,4-DIFLUOROBENZYLIDENECURCUMIN; PAMAM STARBURST;

ARTICLE; ASPC 1 CELL LINE; ATOMIC FORCE MICROSCOPY; CELL MEDIATED CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MIAPACA 2 CELL LINE; MTT ASSAY; PANCREATIC CANCER CELL LINE; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CHEMISTRY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; INFRARED SPECTROSCOPY; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD44; CELL LINE, TUMOR; CURCUMIN; DENDRIMERS; HUMANS; HYALURONIC ACID; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84943374411     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.09.043     Document Type: Article

References (40)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
2. Bunt S.K., Mohr A.M., Bailey J.M., Grandgenett P.M., Hollingsworth M.A. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol. Immunother. 2013, 62:225-236.
3. J.Long Y., Zhang X., Yu J., Yang D.G., LeBrun C.Chen, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin. Ther. Targets 2011, 15:817-828.
4. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control Release 2011, 153:198-205.
5. Kesharwani P., Banerjee S., Padhye S., Sarkar F.H., Iyer A.K. Parenterally administrable nano-micelles of 3, 4-difluorobenzylidene curcumin for treating pancreatic cancers. Colloids Surf. B Biointerfaces 2015, 132:138-145.
6. Kommareddy S., Tiwari S.B., Amiji M.M. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol. Cancer Res. Treat. 2005, 4:615-625.
7. Kesharwani P., Jain K., Jain N.K. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014, 39:268-307.
8. Kesharwani P., Tekade R.K., Jain N.K. Dendrimer generational nomenclature: the need to harmonize. Drug Discov. Today 2015, 20:497-499.
9. Kesharwani P., Banerjee S., Gupta U., Mohd Amin M.C.I., Padhye S., Sarkar F.H., et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater. Today 2015, In press. 10.1016/j.mattod.2015.06.003.
10. Jain S., Kesharwani P., Tekade R.K., Jain N.K. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev. Ind. Pharm. 2015, 41:722-727.
11. Borowska K., Wołowiec S., Głowniak K., Sieniawska E., Radej S. Transdermal delivery of 8-methoxypsoralene mediated by polyamidoamine dendrimer G2.5 and G3.5-in vitro and in vivo study. Int. J. Pharm. 2012, 436:764-770.
12. Sadekar S., Thiagarajan G., Bartlett K., Hubbard D., Ray A., McGill L.D., et al. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int. J. Pharm. 2013, 456:175-185.
13. Kesharwani P., Tekade R.K., Gajbhiye V., Jain K., Jain N.K. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed. Nanotechnol. Biol. Med. 2011, 7:295-304.
14. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
15. Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: let's meet the challenge. Int. J. Pharm. 2010, 394:122-142.
16. Kesharwani P., Mishra V., Jain N.K. Generation dependent hemolytic profile of folate engineered poly(propyleneimine) dendrimer. J. Drug Deliv. Sci. Technol. 2015, 28:1-6.
17. Kesharwani P., Iyer A.K. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov. Today 2015, 20:536-547.
18. Park J.-H., Cho H.-J., Yoon H.Y., Yoon I.-S., Ko S.-H., Shim J.-S., et al. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J. Control. Release 2014, 174:98-108.
19. Zhao Q., Geng H., Wang Y., Gao Y., Huang J., Wang Y., et al. Hyaluronic acid oligosaccharide modified redox-responsive mesoporous silica nanoparticles for targeted drug delivery. ACS Appl. Mater. Interfaces 2014, 6:20290-20299.
20. Padhye S., Banerjee S., Chavan D., Pandye S., Swamy K.V., Ali S., et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26:2438-2445.
21. Padhye S., Yang H., Jamadar A., Cui Q.C., Chavan D., Dominiak K., et al. New difluoro knoevenagel condensates of curcumin, their schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm. Res. 2009, 26:1874-1880.
22. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
23. Bao B., Ali S., Kong D., Sarkar S.H., Wang Z., Banerjee S., et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
24. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72:335-345.
25. Basak S.K., Zinabadi A., Wu A.W., Venkatesan N., Duarte V.M., Kang J.J., et al. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells. Oncotarget 2015, 6:18504-18517.
26. + stem-like pancreatic cancer cells. Biomacromolecules 2015, 16:3042-3053.
27. Kesharwani P., Tekade R.K., Jain N.K. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm. Res. 2015, 32:1438-1450.
28. Kesharwani P., Tekade R.K., Jain N.K. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond.) 2014, 9:2291-2308.
29. Banerjee S., Azmi A.S., Padhye S., Singh M.W., Baruah J.B., Philip P.A., et al. Structure-activity studies on therapeutic potential of thymoquinone analogs in pancreatic cancer. Pharm. Res. 2010, 27:1146-1158.
30. Huang Y., He L., Liu W., Fan C., Zheng W., Wong Y.-S., et al. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 2013, 34:7106-7116.
31. Qi X., Fan Y., He H., Wu Z. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously. Carbohydr. Polym. 2015, 126:231-239.
32. Han M., Lv Q., Tang X.-J., Hu Y.-L., Xu D.-H., Li F.-Z., et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J. Control. Release 2012, 163:136-144.
33. Kesharwani P., Tekade R.K., Gajbhiye V., Jain K., Jain N.K. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 2011, 7:295-304.
34. Chandrasekar D., Sistla R., Ahmad F.J., Khar R.K., Diwan P.V. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007, 28:504-512.
35. Kesharwani P., Tekade R.K., Jain N.K. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials 2014, 35:5539-5548.
36. Liu Y., Bryantsev V.S., Diallo M.S., Goddard W.A. PAMAM dendrimers undergo pH responsive conformational changes without swelling. J. Am. Chem. Soc. 2009, 131:2798-2799.
37. Gary-Bobo M., Brevet D., Benkirane-Jessel N., Raehm L., Maillard P., Garcia M., et al. Hyaluronic acid-functionalized mesoporous silica nanoparticles for efficient photodynamic therapy of cancer cells. Photodiag. Photodyn. Ther. 2012, 9:256-260.
38. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
39. Luo Y., Bernshaw N.J., Lu Z.-R., Kopecek J., Prestwich G.D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 2002, 19:396-402.
40. Birdhariya B., Kesharwani P., Jain N.K. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev. Ind. Pharm. 2014, 1-7.